← Back to headlines
Deutsche Bank Upgrades Merck to Buy, Sees Clear Path Beyond Keytruda Patent Cliff
Deutsche Bank has upgraded Merck (MRK) to a 'Buy' rating, expressing optimism about the company's future beyond the patent expiration of its key drug, Keytruda.
20 Feb, 23:31 — 20 Feb, 23:31
ℹOnly 1 source covers this story
